RxDoctor Payments DataLook up a doctor →

Timothy Freyaldenhoven, MD

Neurology · Conway, ARNPI 1174520258

Payments from drug & device makers

$28,408in general payments, 2019–2025

Across 1,535 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Biogen$2K
  • Novartis$2K
  • Jazz Pharmaceuticals Inc.$2K
  • Amgen$2K
  • EMD Serono, Inc.$1K
  • plus $19K from 54 others

What the payments were for

  • Speaking & faculty fees$2091%
  • Food & beverage$27,87798%
  • Education$3221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)140$1,803
Biogen90$1,772
Novartis82$1,623
Jazz Pharmaceuticals Inc.70$1,529
Amgen63$1,510
EMD Serono, Inc.71$1,324
SK Life Science, Inc.58$1,287
UCB, Inc.48$1,249
MDD US Operations, LLC52$1,219
Pfizer88$1,197
Lundbeck LLC62$1,082
Amneal Pharmaceuticals LLC52$946
Supernus Pharmaceuticals, Inc.47$745
Kyowa Kirin, Inc.40$725
Lilly USA, LLC54$715
Sanofi32$702
Neurocrine Biosciences, Inc.43$683
AstraZeneca(2 entities)39$664
Eisai Inc.30$592
Upsher-smith Laboratories LLC34$535
CSL Behring27$520
Acadia Pharmaceuticals Inc26$493
Biohaven Pharmaceutical Holding Company Ltd.34$490
Harmony Biosciences LLC18$405
Biohaven Pharmaceuticals, Inc.30$398
TG Therapeutics, Inc.14$299
Sunovion Pharmaceuticals Inc.14$275
Bristol Myers Squibb16$251
Argenx US, Inc.11$250
Merz Pharmaceuticals, LLC8$245
Teva Pharmaceuticals USA, Inc.16$232
Acorda Therapeutics, Inc11$199
Neurelis, Inc.8$191
Impel Pharmaceuticals Inc.10$184
Mallinckrodt Hospital Products Inc.8$179
E.r. Squibb & Sons, L.L.C.11$169
Inspire Medical Systems, Inc.2$157
Tanabe Pharma America, Inc.8$135
Livanova USA, Inc.5$130
Axsome Therapeutics, Inc.4$126
Johnson & Johnson6$111
Alnylam Pharmaceuticals Inc.5$103
Grifols USA, LLC4$98
Avanir Pharmaceuticals, Inc.7$89
Nevro Corp.6$84
Banner Life Sciences, LLC3$79
Genentech USA, Inc.4$78
Otsuka America Pharmaceutical, Inc.3$74
Adamas Pharmaceuticals, Inc.3$68
Vertical Pharmaceuticals, LLC2$58
ZOLL Respicardia, Inc.1$57
Avadel CNS Pharmaceuticals, LLC2$47
GE HealthCare2$36
Catalyst Pharmaceuticals, Inc.2$34
Ipsen Biopharmaceuticals, Inc1$32
Avion Pharmaceuticals2$31
Averitas Pharma Inc.1$24
Abbott1$16
Ultragenyx Pharmaceutical Inc.1$16
Resmed Corp1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,408 in reported general payments places this provider in the 80th percentile of 93 neurology providers in Arkansas.

See all neurology providers in Arkansas

Medicare billing

Part B allowed, 2024
$224,043
Medicare patients
1,206
Services billed
2,720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4666$1,029,440
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5031$634,977
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5022$375,150
PanzygaImmun Glob G(Igg)-Ifas/Glycine24$312,947
AubagioTeriflunomide16$155,206
BetaseronInterferon Beta-1b13$123,246
XcopriCenobamate44$54,554
NuplazidPimavanserin Tartrate13$53,251
Emgality PenGalcanezumab-Gnlm60$46,483
Nurtec OdtRimegepant Sulfate25$36,734
QuliptaAtogepant14$17,507
Aimovig AutoinjectorErenumab-Aooe23$15,641
Memantine Hcl333$8,494
Pyridostigmine Bromide62$5,147
Carbidopa-LevodopaCarbidopa/Levodopa176$4,988

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$520$375,15022 claims
PfizerPanzyga, Nurtec Odt$1,197$349,68149 claims
SanofiAubagio$702$155,20616 claims
SK Life Science, Inc.Xcopri$1,287$54,55444 claims
Acadia Pharmaceuticals IncNuplazid$493$53,25113 claims
AbbVieQulipta$1,803$17,50714 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$946$7,770110 claims
Upsher-smith Laboratories LLCTopiramate$535$1,717209 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 93 neurology providers in Arkansas.

Other neurology in Conway

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →